PPH Legal Blog

Alli, the first over-the-counter FDA approved weight-loss drug, is still a weapon for weight-loss. The biggest benefit doctors are seeing is that it’s a lot safer than older weight-loss drugs. They are frequently fielding questions from patients about it’s effectiveness and any side effects. Alli is known to prevent the absorption of fat by the […]

[Read more →]

According to Tomas J Philopson and Eric Sun of the University of Chicago, 55,600 life years have been lost to the speedy approval of drugs following the Prescription Drug User Fee Act. This has been partially attributed to the passage of such drugs as Vioxx, fen-phen, and Baycol. This loss of life translates to between […]

[Read more →]

Doctors at St. Michael’s Hospital in Toronto are currently testing a novel approach to pulmonary hypertension treatment by combining gene and cell therapy to treat the condition. In patients who suffer from PH, the vessels that carry blood from the heart to the lungs becomes hard and narrow, which in turn makes it harder for […]

[Read more →]

CHEST 2007, the scientific assembly of the American College of Chest Physicians, reported that a recent study shows that most patients experience a 1-year delay between the onset of pulmonary arterial hypertension symptoms and a confirmed diagnosis of the disease. The most common symptoms attributable to PAH are dyspnea on exertion, fatigue, chest pain and/or […]

[Read more →]

The US Food and Drug Administration (FDA) has come under fire lately for the manner by which some recent drugs have been approved. However, one former FDA official was upset a decade ago that drugs used in Fen-phen a drug combination linked to primary pulmonary hypertension (PPH), were approved for use. He says he knew early […]

[Read more →]